AbstractBackground. Olorofim is a new antifungal agent with a novel mechanism of action with in vitro activity against Aspergillus fumigatus and other clin

AbstractRandomized trials of procalcitonin-guided algorithms to discontinue antibiotics in critically ill patients with sepsis report reduced antibiotic duration and possible mortality benefit. However, open-label trial designs, inconsistent algorithm adherence, and unclear stewardship practices have limited confidence in procalcitonin’s benefit. The ADAPT-Sepsis trial addressed several of these gaps through a concealed intervention, robust stewardship, and head-to-head comparison with CRP. Procalcitonin-guided care reduced antibiotic use without significantly impacting mortality, while CRP-guided care showed no benefit. However, algorithm adherence was suboptimal and the absolute reduction in antibiotic duration with procalcitonin was only one day. As shorter fixed-duration therapy becomes standard, procalcitonin’s utility in the ICU may decline. Embedding procalcitonin and other biomarkers into multifaceted stewardship strategies, and addressing barriers to clinician trust and implementation, is essential. Future research should also evaluate whether biomarker use earlier in the sepsis care pathway, particularly in Emergency Departments, can improve early diagnostic accuracy and enhance patient outcomes.

Pepfar, which is estimated to have delivered lifesaving treatment as many as 25 million people in 54 countries, faces a funding delay of as long as 180 days.

MMWR did not publish as usual at 1 p.m. today

by enzyme immunoassay (EIA-IgM-only), although this result may be falsely positive. Methods. We conducted a retrospective study at a large-volume transplant center in an endemic coccidioidomycosis ...

Short time to blood culture positivity (TTP) was an independent risk factor of infective endocarditis in this large (N=1703) Staphylococcus aureus bacterem

Click on the article title to read more.